TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage company developing novel therapies for treatment of the most aggressive cancers, announced on Monday that it showcased updated results from the NOX-A12 GLORIA Phase 1/2 trial at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.

Led by Dr Frank A. Giordano, the trial examined the efficacy of combining NOX-A12 with bevacizumab in treating newly diagnosed glioblastoma patients resistant to standard chemotherapy.

The data highlighted a significant improvement in survival rates for patients receiving the NOX-A12 and bevacizumab combination. Compared to standard of care or NOX-A12 alone, the combination therapy resulted in longer median progression-free survival (9.1 months vs. 4.0 months and 5.7 months) and median overall survival (19.9 months vs. 9.5 months and 12.7 months). Additionally, the combination led to a notable decrease in tumor blood flow, reinforcing its mechanism of action.

Titled 'Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial', the presentation took place during the mini oral session on CNS tumors. The trial's findings include that two out of six patients in the NOX-A12 and bevacizumab arm survived beyond 26 months.

TME Pharma is advancing the NOX-A12 programme, with ongoing trials evaluating its combination with radiotherapy and other agents. The FDA has approved a randomized Phase 2 trial design and granted fast track designation to NOX-A12. TME Pharma is also exploring the potential of NOX-A12 in metastatic pancreatic cancer through its OPTIMUS study.